Exploring the Capability and Potential of Genetically Targeted Technology
We were pleased to host a Capitol Hill briefing on Wednesday, March 5, where we explored the powerful potential of genetically targeted technology and the profoundly important impact of RNA-based therapies, including antisense oligonucleotides (ASO) and RNAi, on treatment and prevention. Panelists discussed the science behind these therapies, the extraordinary capability they hold to address urgent unmet medical needs, and challenges and opportunities bearing on the future of this transformative area of research & development.
Moderator: Katie Sale, Executive Director, American Brain Coalition
Panelists:
Victor Ambros, PhD, Professor, University of Mass Chan Medical School
Alison L. Bailey, Chief of Cardiology, Centennial Heart at Parkridge
Kathryn Schubert, President and CEO, Society for Women’s Health Research
Jamie Sullivan, Vice President of Policy, EveryLife Foundation for Rare Diseases
Check out our infographic on genetically targeted technology from the briefing for more.
Research!America’s “Exploring the Capability and Potential of Genetically Targeted Technology” briefing was supported in part by Alnylam Pharmaceuticals, the American Brain Coalition, Eli Lilly and Company, the EveryLife Foundation for Rare Diseases, Ionis Pharmaceuticals, Novartis, and the Society for Women’s Health Research.